Provided by Tiger Fintech (Singapore) Pte. Ltd.

ResMed

277.87
+4.061.48%
Volume:495.96K
Turnover:136.87M
Market Cap:40.68B
PE:29.22
High:277.87
Open:274.10
Low:274.10
Close:273.81
52wk High:293.81
52wk Low:199.92
Shares:146.41M
Float Shares:145.51M
Volume Ratio:0.46
T/O Rate:0.34%
Dividend:2.19
Dividend Rate:0.79%
EPS(TTM):9.51
EPS(LYR):9.55
ROE:25.86%
ROA:14.02%
PB:6.82
PE(LYR):29.10

Loading ...

ResMed Bull Stays Positive on Margin, Earnings -- Market Talk

Dow Jones
·
Jun 03

Is Taking Your Required Minimum Distribution (RMD) in June a Good Idea?

Motley Fool
·
Jun 01

ResMed Inc. Files Conflict Minerals Disclosure Report for 2024

TIPRANKS
·
May 30

ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan

TIPRANKS
·
May 28

ResMed Inc. Stock Rises Tuesday, Still Underperforms Market

Dow Jones
·
May 28

10 Strategic Ways for Retirees to Use Their Required Minimum Distribution (RMD)

Motley Fool
·
May 24

ResMed Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
May 24

Goldman Sachs Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

TIPRANKS
·
May 23

ResMed CFO Sells Shares

MT Newswires Live
·
May 23

Reinvesting Your RMD as a Retiree? Here's What You Need to Know.

Motley Fool
·
May 22

ResMed Inc. Director Jan De Witte Reports Disposal of Common Shares

Reuters
·
May 22

Morgan Stanley Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

TIPRANKS
·
May 21

Should you buy the dip in the ResMed share price?

MotleyFool
·
May 21

ResMed Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
May 21

Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed

TIPRANKS
·
May 20

BUZZ-ResMed falls after rival's sleep apnea drug succeeds in late-stage study

Reuters
·
May 20

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Southern Co, Amer Sports

Reuters
·
May 20

Resmed (RMD) Receives a Hold from Needham

TIPRANKS
·
May 20

Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities

TIPRANKS
·
May 20

Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109’s Appeal

TIPRANKS
·
May 20